| scholarly article | Q13442814 |
| P356 | DOI | 10.2337/DIAB.33.4.346 |
| P698 | PubMed publication ID | 6423429 |
| P50 | author | Jerrold M. Olefsky | Q60573000 |
| P2093 | author name string | Griffin J | |
| Shapiro G | |||
| Gray RS | |||
| Kolterman OG | |||
| Scarlett JA | |||
| P2860 | cites work | Insulin Sensitivity and Insulin Binding to Monocytes in Maturity-Onset Diabetes | Q37038173 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 346-354 | |
| P577 | publication date | 1984-04-01 | |
| P1433 | published in | Diabetes | Q895262 |
| P1476 | title | The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects. | |
| P478 | volume | 33 |
| Q44169307 | Abnormality in fibre type distribution of soleus and plantaris muscles in non-obese diabetic Goto-Kakizaki rats |
| Q57931390 | Cardiovascular Disease and Diabetes: Two Sides of the Same Coin! |
| Q37385345 | Central nervous system nitric oxide synthase activity regulates insulin secretion and insulin action |
| Q51612756 | Changes in Carbohydrate Metabolism in Association With Glipizide Treatment of Type 2 Diabetes |
| Q51636948 | Combination insulin/glyburide therapy in type II diabetes mellitus. Effects on lipoprotein metabolism and glucoregulation. |
| Q39557893 | Correlation of in vivo and in vitro actions of insulin in obesity and noninsulin-dependent diabetes mellitus: role of the glucose transport system |
| Q34290241 | Dangerous misuse of sulphonylureas |
| Q40623938 | Drugs and insulin resistance: clinical methods of evaluation and new pharmacological approaches to metabolism |
| Q33610761 | Early insulin use in type 2 diabetes: what are the cons? |
| Q41015653 | Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. |
| Q51607455 | Effects of a combination of bedtime intermediate-acting insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to respond to oral hypoglycaemic agents. |
| Q42446315 | Enhancement of glucose uptake in 3T3-L1 adipocytes by Toona sinensis leaf extract |
| Q42528066 | Fat cells: model system to investigate molecular mechanism(s) of sulfonylurea-potentiated glucose transport |
| Q35768419 | Glucosamine induces insulin resistance in vivo by affecting GLUT 4 translocation in skeletal muscle. Implications for glucose toxicity |
| Q37039960 | Hypoglycaemic and anti-hyperglycaemic drugs for the control of diabetes |
| Q40362406 | Impact of insulin sensitivity, beta-cell function and glycaemic control on initiation of second-line glucose-lowering treatment in newly diagnosed type 2 diabetes. |
| Q70634882 | Insulin resistance and mechanical dysfunction in hearts of Wistar rats with streptozotocin-induced non-insulin-dependent diabetes mellitus |
| Q41166028 | Insulin resistance in non-insulin-dependent diabetes mellitus. A review |
| Q69967177 | Longitudinal evaluation of the effects of sulfonylurea therapy in subjects with type II diabetes mellitus |
| Q41204980 | Low dose metformin in the treatment of type II non-insulin-dependent diabetes: clinical and metabolic evaluations |
| Q51598308 | Mechanism(s) of the blood glucose lowering action of benfluorex. |
| Q37721470 | Mechanistic Insight and Management of Diabetic Nephropathy: Recent Progress and Future Perspective. |
| Q40474368 | NIDDM in the Cat: Treatment with the Oral Hypoglycemic Medication, Glipizide |
| Q41716386 | Non-insulin dependent diabetes in children and adolescents: the therapeutic challenge |
| Q41327011 | Non-insulin-dependent diabetes mellitus. Current status of oral hypoglycemic therapy |
| Q51613996 | On the determination of basal glucose production rate in patients with type 2 (non-insulin-dependent) diabetes mellitus using primed-continuous 3-3H-glucose infusion. |
| Q69967189 | Once-daily use of glyburide |
| Q41277363 | Oral antidiabetic drug use in the elderly |
| Q34708953 | Oral hypoglycaemic agents. An update |
| Q26766485 | Pancreatic regulation of glucose homeostasis |
| Q38631248 | Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update |
| Q44218568 | Pharmacokinetics of glyburide |
| Q44620870 | Phosphatidylinositol 3-Kinase Activation Is Required for Sulfonylurea Stimulation of Glucose Transport in Rat Skeletal Muscle |
| Q33756059 | Post-meal β-cell function predicts the efficacy of glycemic control in patients with type 2 diabetes inadequately controlled by metformin monotherapy after addition of glibenclamide or acarbose |
| Q40923073 | Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM). |
| Q37166016 | Short-Term High-Fat Diet (HFD) Induced Anxiety-Like Behaviors and Cognitive Impairment Are Improved with Treatment by Glyburide |
| Q51730069 | Simultaneous Determination of Bosentan, Glimepiride, HYBOS and M1 in Rat Plasma by UPLC-MS-MS and its Application to Pharmacokinetic Study. |
| Q42005197 | Skeletal Muscle TRIB3 Mediates Glucose Toxicity in Diabetes and High- Fat Diet-Induced Insulin Resistance |
| Q51607493 | Studies on the mechanism of action of sulphonylureas in type II diabetic subjects: gliquidone. |
| Q71293159 | Sulphonylurea stimulates glucose uptake in rats through an ATP-sensitive K+ channel dependent mechanism |
| Q51636422 | Sulphonylurea therapy doubles B-cell response to glucose in type 2 diabetic patients. |
| Q37333602 | TRIB3 mediates glucose-induced insulin resistance via a mechanism that requires the hexosamine biosynthetic pathway |
| Q51611436 | The Effect of Sulphonylurea Therapy on Skeletal Muscle Glycogen Synthase Activity and Insulin Secretion in Newly Presenting Type 2 (Non-insulin-dependent) Diabetic Patients |
| Q36660303 | The Management of Diabetes Mellitus in Older Individuals |
| Q39650599 | The biochemistry of diabetes |
| Q34446999 | The effect of liver microsomal enzyme inducing and inhibiting drugs on insulin mediated glucose metabolism in man |
| Q44959251 | The morphological and biochemical effects of glibornuride on rat liver in experimental diabetes |
| Q36694998 | The sulphonylurea drug, glimepiride, stimulates release of glycosylphosphatidylinositol-anchored plasma-membrane proteins from 3T3 adipocytes |
Search more.